Axsome Therapeutics, Inc. (AXSM) stock
AXSMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 8/30
$134.00−1.95 (-1.43%)
Close on Nov 18, 2026Market cap $7.02BP/E –Yield –
Axsome Therapeutics gross margin
Gross margin is gross profit as a percentage of revenue.
Axsome Therapeutics's gross margin for the twelve months ending Jun 30, 2026 was 93.2%. For fiscal 2025 it was 92.6%, against 91.4% the year before.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 92.6% | +1.2 |
| FY2024 | Dec 31, 2024 | 91.4% | +1.0 |
| FY2023 | Dec 31, 2023 | 90.4% | +0.8 |
| FY2022 | Dec 31, 2022 | 89.6% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 93.8% | +2.8 |
| Q1 FY2026 | Mar 31, 2026 | 92.3% | +0.4 |
| Q4 FY2025 | Dec 31, 2025 | 93.7% | +2.6 |
| Q3 FY2025 | Sep 30, 2025 | 93.0% | +1.1 |
| Q2 FY2025 | Jun 30, 2025 | 91.0% | +0.3 |
| Q1 FY2025 | Mar 31, 2025 | 91.9% | +0.3 |
| Q4 FY2024 | Dec 31, 2024 | 91.1% | +1.5 |
| Q3 FY2024 | Sep 30, 2024 | 91.9% | +3.2 |
| Q2 FY2024 | Jun 30, 2024 | 90.8% | +0.6 |
| Q1 FY2024 | Mar 31, 2024 | 91.6% | −0.4 |
| Q4 FY2023 | Dec 31, 2023 | 89.7% | −0.9 |
| Q3 FY2023 | Sep 30, 2023 | 88.7% | +0.1 |
| Q2 FY2023 | Jun 30, 2023 | 90.2% | +1.3 |
| Q1 FY2023 | Mar 31, 2023 | 92.0% | – |
| Q4 FY2022 | Dec 31, 2022 | 90.6% | – |
| Q3 FY2022 | Sep 30, 2022 | 88.6% | – |
| Q2 FY2022 | Jun 30, 2022 | 88.9% | – |
See a number that looks wrong?